PharVision Advisers’s Century Aluminum CENX Stock Holding History

PharVision Advisers’s Portfolio CENX Stock Details CENX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16,022	Closed	-$628K	–	198
2025 Q4	$628K	Buy	16,022 +6,143	+62%	+$192K	0.32%	13
2025 Q3	$290K	Buy	+9,879	New	+$224K	0.16%	244

Other funds holding CENX

Glencore Baar, Switzerland $4.87B AUM 67.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PharVision Advisers's CENX Position: Q1 2026 in Review

PharVision Advisers sold out of Century Aluminum (CENX) in Q1 2026, closing a stake of 16,022 shares — an estimated $628K sold.

PharVision Advisers first reported a position in CENX in Q3 2025 and held it in 2 quarters. The position peaked at $628K in Q4 2025. 386 funds tracked by Wall St. Rank hold CENX as of Q1 2026.

PharVision Advisers reported no remaining Century Aluminum position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 16,022 Century Aluminum shares in Q1 2026, an estimated $628K.
PharVision Advisers first reported a position in Century Aluminum in Q3 2025 and held it in 2 quarters.
PharVision Advisers's Century Aluminum position peaked at $628K in Q4 2025.
386 funds tracked by Wall St. Rank held Century Aluminum as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.